AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Pharmaceutical Companies

676.364

+8.9191.34%

Number of Gainers:7

Number of Losers:12

Number of Flat:24

PE:- -

High:677.895

Open:665.383

Low:665.263

Close:667.445

Volume:39.56M

Turnover:207.18M

Market Cap:96.88B

Float Cap:93.75B

Loading ...

ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug

MT Newswires Live

Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive Director

Immutep - Pete Meyers Resigns as Non-Executive Director and Deputy Chairman Effective Oct 2, 2026

THOMSON REUTERS

Immutep Ltd-Resignation of Non-Executive Director

THOMSON REUTERS

CSL Enters Global Lixudebart Partnership with Alentis, Pays Us$355 Million Upfront

CSL and Alentis Announce Global Partnership to Develop and Commercialise Lixudebart for Rare Kidney and Liver Diseases

THOMSON REUTERS

Australia's CSL Strikes Kidney, Liver Disease Drug Deal Worth up to $1.6 Billion

To Pay Alentis $355 Mln Upfront and up to $1.2 Bln in Milestones

THOMSON REUTERS

To Fully Fund Phase 2 and Phase 3 Trials for Lixudebart

THOMSON REUTERS

CSL Limited-CSL Enters Exclusive Agreement with Alentis Therapeutics

THOMSON REUTERS

Enters Agreement with Alentis to Co-Develop and Co-Promote Lixudebart

THOMSON REUTERS

How Honeycomb Qualification At Hexcel (HXL) Has Changed Its Investment Story

Simply Wall St.

What Has Actually Changed At PolyNovo (PNV)?

Simply Wall St.

Orthocell Ltd-Change of Auditor

THOMSON REUTERS

US FDA Advisers Recommend Flu Vaccine Strains for 2027 Southern Hemisphere Season

Starpharma Holdings Appoints Russell Basser as Chair

Starpharma - Rob Thomas Ao to Retire as Chair at Conclusion of 2026 AGM

THOMSON REUTERS

Starpharma Holdings Ltd-Chair and Deputy Chair Appointments

THOMSON REUTERS

Imricor's Stock Weakness Creates 'Great Buying Opportunity'

ASX Growth Companies With High Insider Ownership September 2026

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/BK7508/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK7508","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","market":"AU","secType":"PLATE","nameCN":"Pharmaceutical Companies","latestPrice":676.3637,"timestamp":1791349200017,"preClose":667.4446,"halted":0,"volume":39560326,"delay":0,"changeRate":0.013363,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":8.919128,"latestTime":"10-07 16:00:00 AEDT","open":665.3829,"high":677.895,"low":665.26276,"amount":207175666,"amplitude":0.018926,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791414000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1791327600000,1791349200000]],"turnoverRate":0.001573,"increases":7,"decrements":12,"flats":23,"marketCap":96881580350.75,"floatMarketCap":93754575299.875},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK7508\",,,,,undefined,":{"symbol":"BK7508","high":677.895,"amplitude":0.018926,"preClose":667.4446,"low":665.26276,"latestPrice":676.3637,"volume":39560326,"delay":0,"open":665.3829,"prevYearClose":644.3692,"prevWeekClose":654.21,"prevMonthClose":689.549,"prevQuarterClose":689.549,"fiveDayClose":689.549,"twentyDayClose":655.041,"sixtyDayClose":491.903,"secType":"PLATE","market":"AU","turnoverRate":0.001573,"marketCap":96881580350.75,"floatMarketCap":93754575299.875,"timestamp":1791349200017,"nameCN":"Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK7508\",,,,undefined,":{"bkCode":"BK7508","up":7,"down":12,"flat":24},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK7508\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673776492","title":"ASX Preview: Australian Shares to Rise as Oil Climbs on Saudi Attacks; CSL Partners With Alentis Therapeutics to Develop Rare Kidney, Liver Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776492","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776492?lang=en_us&edition=fundamental","pubTime":"2026-10-05 07:07","pubTimestamp":1791155252,"startTime":"0","endTime":"0","summary":"Australian shares are poised to rise on Monday after oil prices climbed as attacks claimed by Yemen's Iran-backed Houthis on Saudi Aramco sites raised concerns about potential disruptions to crude production.Oil prices were also supported after the Organization of the Petroleum Exporting Countries decided to keep its November output targets unchanged, limiting expectations for additional supply and helping keep Brent crude above $100 a barrel amid the Iran war.On Oct. 2, the S&P 500, the Nasdaq Composite, and the Dow Jones Industrial Average rose 0.7%, 1.2%, and 0.5%, respectively.In the macroeconomy, Australia's private-sector growth slowed in September as weaker new business weighed on services activity, prompting a resumption of job cuts while inflationary pressures intensified, according to a monthly survey by S&P Global released Monday.In corporate news, CSL  entered a partnership with Alentis Therapeutics to co-develop and co-promote lixudebart, a potential first-in-class therapy","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IIGF.AU","QRE.AU","STW.AU","IMLC.AU","BEAR.AU","BBOZ.AU","BK4139","OZR.AU","E200.AU","VAS.AU","EIGA.AU","BK7067","BK7508","BK4007","OZF.AU","BK4539","CMM.AU","GEAR.AU","GIVE.AU","ZYAU.AU","LENZ","QFN.AU","XKO.AU","IOZ.AU","BK7511","BK7501","CSL.AU","VAP.AU","BK7104","SLF.AU","XJO.AU","IISV.AU","XAO.AU","DACE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673377697","title":"Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2673377697","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673377697?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:42","pubTimestamp":1791153759,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive DirectorOct 5 (Reuters)-Immutep LtdIMM.AX:RESIGNATION OF NON-EXECUTIVE DIRECTORPETE MEYERS RESIGNS AS NON-EXECUTIVE DIRECTOR AND DEPUTY CHAIRMAN EFFECTIVE OCT 2, 2026Further company coverage:IMM.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776981","title":"Immutep - Pete Meyers Resigns as Non-Executive Director and Deputy Chairman Effective Oct 2, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776981","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776981?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:37","pubTimestamp":1791153477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673677698","title":"Immutep Ltd-Resignation of Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2673677698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673677698?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:37","pubTimestamp":1791153477,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673768577","title":"CSL Enters Global Lixudebart Partnership with Alentis, Pays Us$355 Million Upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2673768577","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673768577?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:42","pubTimestamp":1791150175,"startTime":"0","endTime":"0","summary":"CSL enters global lixudebart partnership with Alentis, pays US$355 million upfrontCSL entered an exclusive global collaboration with Alentis Therapeutics to co-develop, co-promote lixudebart for rare ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nNDL9fTHVp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","BK7508","BK7067","CSL.AU","BK7511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776854","title":"CSL and Alentis Announce Global Partnership to Develop and Commercialise Lixudebart for Rare Kidney and Liver Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776854","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776854?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:42","pubTimestamp":1791150151,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUABRZMKD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7067","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673750477","title":"Australia's CSL Strikes Kidney, Liver Disease Drug Deal Worth up to $1.6 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2673750477","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673750477?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:37","pubTimestamp":1791149849,"startTime":"0","endTime":"0","summary":"Australia's CSL strikes kidney, liver disease drug deal worth up to $1.6 billionOct 5 -Australia's CSLCSL.AXsaid on Monday it had entered into an agreement with Switzerland-based Alentis Therapeutics to co-develop and co-promote a treatment for rare kidney and liver diseases, in a deal worth up to $1.6 billion before development funding.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nL1N45Q05Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7511","CSL.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775745","title":"To Pay Alentis $355 Mln Upfront and up to $1.2 Bln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775745","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775745?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775723","title":"To Fully Fund Phase 2 and Phase 3 Trials for Lixudebart","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775723","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775723?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775717","title":"CSL Limited-CSL Enters Exclusive Agreement with Alentis Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775717","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775717?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7511","BK7508","CSL.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673775710","title":"Enters Agreement with Alentis to Co-Develop and Co-Promote Lixudebart","url":"https://stock-news.laohu8.com/highlight/detail?id=2673775710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673775710?lang=en_us&edition=fundamental","pubTime":"2026-10-05 05:22","pubTimestamp":1791148963,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE73SZKR:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7511","BK7067","CSL.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672174636","title":"How Honeycomb Qualification At Hexcel (HXL) Has Changed Its Investment Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2672174636","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672174636?lang=en_us&edition=fundamental","pubTime":"2026-10-03 01:28","pubTimestamp":1790962113,"startTime":"0","endTime":"0","summary":"Hexcel showcased new composite materials at CAMX 2026, including NCAMP-qualified HexWeb HRH-10 honeycomb, expanded U.S. production of fast-curing HexPly M901, and an upgraded Vented Flex-Core aluminum honeycomb for complex aerospace structures.\nThe NCAMP qualification of HRH-10 creates the first public aerospace honeycomb database, which can cut customer design and certification costs and potentially increase Hexcel’s role in future composite programs.\nWe will now assess how Hexcel’s...","market":"nz","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3021000-choice1-card/1788942963390","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/3021000-choice1-card/1788942963390"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/how-honeycomb-qualification-at-hexcel-hxl-has-changed-its-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/capital-goods/nyse-hxl/hexcel/news/how-honeycomb-qualification-at-hexcel-hxl-has-changed-its-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0205193047.USD","ROKT","LU0240877869.USD","LU0205194284.USD","LU0053671581.USD","LU0240878834.USD","BK7067","HXL","BZZ","BK4187","BK7508","HXL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672199877","title":"What Has Actually Changed At PolyNovo (PNV)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2672199877","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672199877?lang=en_us&edition=fundamental","pubTime":"2026-10-02 17:29","pubTimestamp":1790933377,"startTime":"0","endTime":"0","summary":"If you had paused on PolyNovo in late 2025 because the bullish and bearish analyst targets seemed too far apart to trust, the past year probably feels like a narrow escape. Investors who held PolyNovo over the past year are down 39.5%, including dividends. Recent results show higher revenue with a thinner net margin. The key question is simple: Which early clues about pricing power, product concentration, or regulation would you have wanted to stress test before committing?\nIf the move has...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6022000-choice1-card/1788992506868"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/what-has-actually-changed-at-polynovo-pnv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-pnv/polynovo-shares/news/what-has-actually-changed-at-polynovo-pnv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","BK7126","PNV.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672793108","title":"Orthocell Ltd-Change of Auditor","url":"https://stock-news.laohu8.com/highlight/detail?id=2672793108","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672793108?lang=en_us&edition=fundamental","pubTime":"2026-10-02 09:04","pubTimestamp":1790903059,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nTUECB442V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","OCC.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672766765","title":"US FDA Advisers Recommend Flu Vaccine Strains for 2027 Southern Hemisphere Season","url":"https://stock-news.laohu8.com/highlight/detail?id=2672766765","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672766765?lang=en_us&edition=fundamental","pubTime":"2026-10-02 01:01","pubTimestamp":1790874064,"startTime":"0","endTime":"0","summary":"US FDA advisers recommend flu vaccine strains for 2027 Southern Hemisphere seasonOct 1 (Reuters)-A panel of advisers to the US FDA on Thursday recommended the virus strains vaccine manufacturers shoul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nL4N45M0VF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7511","BK7067","BK7501","CSL.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672073681","title":"Starpharma Holdings Appoints Russell Basser as Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2672073681","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672073681?lang=en_us&edition=fundamental","pubTime":"2026-10-01 09:51","pubTimestamp":1790819484,"startTime":"0","endTime":"0","summary":"BRIEF-Starpharma Holdings Appoints Russell Basser As ChairOct 1 (Reuters)-Starpharma Holdings LtdSPL.AX:CHAIR AND DEPUTY CHAIR APPOINTMENTSAPPOINTS RUSSELL BASSER AS CHAIR AND DAVID MCINTYRE AS DEPUTY","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUE5DHXTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7501","SPL.AU","BK7508","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672832735","title":"Starpharma - Rob Thomas Ao to Retire as Chair at Conclusion of 2026 AGM","url":"https://stock-news.laohu8.com/highlight/detail?id=2672832735","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672832735?lang=en_us&edition=fundamental","pubTime":"2026-10-01 08:44","pubTimestamp":1790815481,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUE5DHXTY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPL.AU","BK7508","BK7501","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672673588","title":"Starpharma Holdings Ltd-Chair and Deputy Chair Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2672673588","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672673588?lang=en_us&edition=fundamental","pubTime":"2026-10-01 08:44","pubTimestamp":1790815481,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUE5DHXTY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SPL.AU","BK7096","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672710738","title":"Imricor's Stock Weakness Creates 'Great Buying Opportunity'","url":"https://stock-news.laohu8.com/highlight/detail?id=2672710738","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672710738?lang=en_us&edition=fundamental","pubTime":"2026-10-01 07:18","pubTimestamp":1790810280,"startTime":"0","endTime":"0","summary":"2318 GMT - A more than 20% fall in the share price of Imricor Medical Systems since it entered the ASX 300 index in early September creates a great buying opportunity for investors, according to its bull at Morgans. Imricor ended Wednesday at A$1.585, having traded as high as A$2.07 in August. Morgans suggests seasonal weakness and rising interest rates may have contributed to the share-price fall. Recent news flow has been positive. \"As we move into a seasonally stronger part of the year, together with our view that material news flow  is expected, we believe the share price should move back over A$2.00,\" Morgans' analyst Scott Power says. Morgans has a speculative buy call on Imricor.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7503","BK7007","IMR.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672411738","title":"ASX Growth Companies With High Insider Ownership September 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2672411738","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672411738?lang=en_us&edition=fundamental","pubTime":"2026-10-01 03:08","pubTimestamp":1790795293,"startTime":"0","endTime":"0","summary":"In the wake of the recent RBA rate increase, the Australian market is experiencing a period of volatility, with mixed signals from global markets and fluctuating commodity prices adding to investor uncertainty. Amidst these conditions, growth companies with high insider ownership can offer unique insights into potential resilience and alignment between management and shareholder interests, making them noteworthy in today's economic climate.","market":"us","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-growth-companies-with-high-insider-ownership-september-2-5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/asx-growth-companies-with-high-insider-ownership-september-2-5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["GEAR.AU","BK4108","ZYAU.AU","EMR.AU","BK7137","BK7084","FRS.AU","IIGF.AU","BK4526","BK4552","OZF.AU","PDI.AU","QRE.AU","VAS.AU","XJO.AU","IMLC.AU","BK7104","GIVE.AU","BK7508","AEM.AU","BK7501","STW.AU","BK7095","AR1.AU","BK4531","DACE.AU","AV1.AU","IQ","SPL.AU","OZR.AU","XAO.AU","XKO.AU","EIQ.AU","VAP.AU","BK7017","EIGA.AU","SLF.AU","BEAR.AU","ELS.AU","E200.AU","GYG.AU","IOZ.AU","MSB.AU","BBOZ.AU","SKS.AU","WZR.AU","BK7023","BK7093","QFN.AU","IISV.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":2,"totalSize":84,"code":"91000000","status":"200"}]}}